GlassScriptPhysician profile
James Atkinson Deer
NPI 1952538027
$13,148.04
in general payments reported to CMS, 2019-2025
61 companies · $2,902 in 2025
The $2,902 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.81 · 2020: $908 · 2021: $2,394 · 2022: $2,349 · 2023: $2,250 · 2024: $2,319 · 2025: $2,902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,470.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,290.93 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,117.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $825.28 | 2020-2025 | Jardiance |
| Corcept Therapeutics | $750.34 | 2020-2025 | Korlym |
| Abbvie INC. | $690.11 | 2020-2025 | Synthroid |
| Amgen INC. | $566.44 | 2020-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $550.31 | 2019-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $514.74 | 2021-2025 | Isturisa, Signifor Lar |
| Radius Health, INC. | $465.23 | 2022-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $449.86 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $424.76 | 2020-2025 | Farxiga |
| Medtronic, INC. | $421.64 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $342.06 | 2020-2024 | |
| Mannkind Corporation | $304.68 | 2020-2025 | Afrezza |
| Cequr Corporation | $302.99 | 2023-2025 | Cequr Simplicity |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $292.53 | 2020-2022 | |
| Insulet Corporation | $270.60 | 2021-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $253.23 | 2020-2025 | Unithroid |
| Zealand Pharma US, INC. | $239.90 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.41 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $201.09 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Aimmune Therapeutics, INC. | $161.72 | 2024-2025 | Zenpep |
| Abbott Laboratories | $147.20 | 2021-2025 | Freestyle Libre 3 |
| Intuity Medical INC | $141.47 | 2022 | |
| Tolmar, INC. | $129.91 | 2024-2025 | Jatenzo |
| Alexion Pharmaceuticals, INC. | $124.62 | 2024-2025 | Strensiq |
| Antares Pharma, INC. | $114.97 | 2021-2024 | Xyosted |
| Amryt Pharma Holdings LTD | $111.87 | 2022-2023 | Mycapssa |
| Ibsa Pharma INC. | $108.09 | 2020-2025 | Tirosint, Flector, Licart |
| Currax Pharmaceuticals LLC | $101.52 | 2022-2024 | Contrave, Nexletol, Nexlizet |
| Ascensia Diabetes Care US INC. | $100.64 | 2022-2025 | |
| Pfizer INC. | $96.83 | 2022-2025 | |
| Sequel Med Tech, LLC | $94.30 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $91.94 | 2024-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $80.52 | 2020-2023 | Nexletol |
| Ipsen Biopharmaceuticals, INC | $79.55 | 2021-2023 | Somatuline Depot |
| Eusa Pharma (US) LLC | $72.90 | 2022 | |
| Horizon Therapeutics Plc | $67.59 | 2020-2023 | Tepezza |
| Beta Bionics, INC. | $64.61 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic Minimed, INC. | $62.53 | 2020 | |
| Verity Pharmaceuticals INC. | $61.45 | 2024-2025 | Tlando |
| Amphastar Pharmaceuticals, INC. | $55.07 | 2023-2025 | Baqsimi |
| Averitas Pharma INC. | $45.49 | 2025 | Qutenza |
| Alnylam Pharmaceuticals INC. | $42.92 | 2023 | Givlaari |
| Ultragenyx Pharmaceutical INC. | $42.82 | 2022 | |
| Nestle Healthcare Nutrition INC. | $39.13 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.27 | 2020-2021 | |
| Clarus Therapeutics INC. | $35.31 | 2021 | |
| Embecta Corp. | $35.12 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Nevro Corp. | $34.51 | 2022-2023 | Senza |
| Acella Pharmaceuticals, LLC | $33.77 | 2023-2025 | NP Thyroid 60 |
| Astellas Pharma US INC | $33.18 | 2025 | Veozah |
| Madrigal Pharmaceuticals | $31.18 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $28.67 | 2023 | Crysvita |
| Novartis Pharmaceuticals Corporation | $24.79 | 2025 | |
| Halozyme INC | $24.49 | 2023 | |
| Grt US Holding, INC. | $23.15 | 2021 | |
| Alvogen INC | $21.88 | 2025 | Teriparatide |
| Acerus Pharmaceuticals Corporation | $17.10 | 2022 | |
| Rgh Enterprises LLC | $16.00 | 2025 | |
| Vistapharm, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Deer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.